Tuesday, October 13, 2026

EUR/CHF Went Down By Over 1% In The Last 21 Sessions

EUR/CHF Went Down By Over 1% In The Last 21 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.54% for the last 21 sessions. At 04:06 EST on Monday, 27 March, EUR/CHF (EURCHF) is $0.99.

EUR/CHF's yearly highs and lows, it's 4.666% up from its 52-week low and 6.135% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.05%, a negative 0.08%, and a positive 0.33%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.38% (last week), 0.35% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy portrays four-day downtrend near 130.50 with eyes on Japan/us inflation clues. According to FXStreet on Monday, 27 March, "It should be noted that Friday's mixed details of the US Durable Goods Orders and Purchasing Managers' Index for February and March respectively joined the hawkish Fed speak to trigger the USD/JPY pair's corrective bounce off the multi-day low.", "Should the inflation numbers print strong outcomes, the greenback has scope for recovery and can allow the USD/JPY to pare recent losses."
  • Usd/jpy: neutral view amidst global banking turmoil – morgan stanley. According to FXStreet on Monday, 27 March, "Analysts at Morgan Stanley shift their view on the USD/JPY pair to neutral from their previous long recommendation.", "With the risk of the market pricing in further policy convergence, we close our long USD/JPY position and turn neutral until things become much clearer."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com